-, TECHNETIUM (99MTC) COMPOUNDS, -, JNJ-56021927
56021927PCR3015
Phase 3 small_molecule active
Quick answer
-, TECHNETIUM (99MTC) COMPOUNDS, -, JNJ-56021927 for High risk recurrent prostate cancer previously treated with radical prostatectomy is a Phase 3 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen-Cilag International N.V.
- Indication
- High risk recurrent prostate cancer previously treated with radical prostatectomy
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active